Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Autoimmune Disease

NCT06557265 is registered in ClinicalTrials.gov with Nkarta, Inc. as lead sponsor.

NCT NCT06557265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06557265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Autoimmune Disease
Lead sponsor
Nkarta, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 13, 2024
Completion date
April 30, 2027
Enrollment
120 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis, primary membranous nephropathy